Last Updated : December 22, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
TBC | delgocitinib | Chronic hand eczema | Received | |||
TBC | datopotamab deruxtecan | advanced or metastatic non-squamousnon-small cell lung cancer (NSCLC) | Cancelled | |||
TBC | risperidone | Schizophrenia, adults | Suspended | |||
TBC | pegcetacoplan | Geographic atrophy secondary to age-related macular degeneration | Active | |||
TBC | Efanesoctocog alfa | congenital factor VIII deficiency | Active | |||
TBC | belantamab mafodotin, bortezomib, dexamethasone | Previously treated multiple myeloma | Pending | |||
TBC | belantamab mafodotin, pomalidomide, dexamethasone | Previously treated multiple myeloma | Pending | |||
TBC | dabrafenib-trametinib | Pediatric low grade glioma (ped LGG) | Active | |||
TBC | fecal microbiota | Clostridioides difficile infection, prevention | Pending | |||
TBC | nemolizumab | Prurigo nodularis (PN) | Pending |